Skip to content
Finance Investment, Medical Health Aged Care

Medicinal cannabis company Little Green Pharma (ASX:LGP) records record quarterly revenue and cash receipts

Little Green Pharma 3 mins read

RECORD REVENUE AND CASH RECEIPTS FOR QUARTER AND FINANCIAL YEAR,

POSITIVE OPERATING CASHFLOW FOR FY24 OF $0.5 MILLION

 

Highlights 

  • Record quarterly cash receipts of $8.1 million, up over 50% on previous quarter and over 20% on previous corresponding period
  • Record quarterly revenue of $7.3 million (unaudited), up 34% on previous quarter and over36% on previous corresponding period
  • Record revenue of $25.6million (unaudited) for FY24, up nearly 30% on previous financial year resulting in positive operating cashflow of $0.5million for financial year
  • Cannabis legalised in Germany with its removal from the Narcotics List
  • Cash in bank of $5.0 million at 31 March 2024 up from $3.7 million at 31 December 2023

To view a copy of the company's Quarterly Activities Report lease click here

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

 


About us:

About Little Green Pharma Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution. The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains. Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets. The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems. For more information about Little Green Pharma go to: www.littlegreenpharma.comAbout Little Green PharmaLittle Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.For more information about Little Green Pharma go to: www.littlegreenpharma.comAbout Little Green PharmaLittle Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.For more information about Little Green Pharma go to: www.littlegreenpharma.com


Contact details:

David Tasker 

Chapter One Advisots

E: dtasker@chapteroneadvisors.com.au 

M: 0433 112 936

Media

More from this category

  • Medical Health Aged Care
  • 18/10/2024
  • 10:22
Royal Australian College of GPs

‘Fantastic milestone’ for 88 new specialist GPs in South Australia

The Royal Australian College of GPs will welcome 88 new fellows as specialist GPs in South Australia at a ceremony on Saturday 19 October, which will also celebrate the state’s annual RACGP Award winners. The new GPs attending the event in Adelaide Town Hall will include eight rural generalists – GPs who’ve completed Additional Rural Skills Training in fields such as anaesthesia and obstetrics. Fellowship of the RACGP (FRACGP) reflects a doctor’s qualification and expertise as a specialist GP and is the culmination of around 11 years of education, training, rigorous assessment, and experience in primary care. RACGP President Dr…

  • Medical Health Aged Care, Science
  • 18/10/2024
  • 09:30
Centenary Institute

Revealing the role of immune cells in liver cancer

New research from the Centenary Institute and the University of Sydney has uncovered important insights into the immune environment within liver cancer, the sixth…

  • Contains:
  • Medical Health Aged Care
  • 18/10/2024
  • 06:35
Royal Australian College of GPs

ACT Labor’s proposed walk-in centres expansion leaves cost and care questions unanswered: RACGP

The Royal Australian College of GPs (RACGP) has reiterated its call for the next ACT government to commit to an independent evaluation of the ACT nurse-led walk-in centres. With ACT Labor announcing an expansion of centres which are reportedly bleeding taxpayers’ money, ahead of this Saturday’s election, the RACGP also gave its assessment of parties’ primary care policies. An independent evaluation of the centres has been a core pillar of the RACGP’s ACT election platform since before a Canberra Times investigation revealed health officials had “buried” $10 million in expenses. Emails obtained under a Canberra Times freedom of information request…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.